Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First experience of a hemophilia monitoring platform: florio HAEMO.
Zapotocka E, Batorova A, Bilic E, Boban A, Escuriola Ettingshausen C, Faganel Kotnik B, Hrdlickova R, Laguna P, Machal J, Nemes L, Zupan IP, Puras G, Zombori M. Zapotocka E, et al. Among authors: nemes l. Res Pract Thromb Haemost. 2022 Mar 13;6(2):e12685. doi: 10.1002/rth2.12685. eCollection 2022 Feb. Res Pract Thromb Haemost. 2022. PMID: 35308098 Free PMC article.
Common large partial VWF gene deletion does not cause alloantibody formation in the Hungarian type 3 von Willebrand disease population.
Mohl A, Boda Z, Jager R, Losonczy H, Marosi A, Masszi T, Nagy E, Nemes L, Obser T, Oyen F, Radványi G, Schlammadinger Á, Szélessy ZS, Várkonyi A, Vezendy K, Vilimi B, Schneppenheim R, Bodó I. Mohl A, et al. Among authors: nemes l. J Thromb Haemost. 2011 May;9(5):945-52. doi: 10.1111/j.1538-7836.2011.04250.x. J Thromb Haemost. 2011. PMID: 21362127 Free article.
Pharmacokinetics, efficacy and safety of IMMUNATE solvent/detergent (IMMUNATE S/D) in previously treated patients with severe hemophilia A: results of a prospective, multicenter, open-label phase III study.
Nemes L, Lissitchkov T, Dobaczewski G, Klukowska A, Komrska V, Zimmermann R, Auerswald G, Engl W, Abbühl B, Pavlova BG, Ehrlich HJ. Nemes L, et al. Acta Haematol. 2008;119(2):89-97. doi: 10.1159/000118628. Epub 2008 Feb 28. Acta Haematol. 2008. PMID: 18305381 Clinical Trial.
Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia.
Gruppo RA, Malan D, Kapocsi J, Nemes L, Hay CRM, Boggio L, Chowdary P, Tagariello G, von Drygalski A, Hua F, Scaramozza M, Arkin S; Marzeptacog alfa (activated) Study Group Investigators. Gruppo RA, et al. Among authors: nemes l. J Thromb Haemost. 2018 Oct;16(10):1984-1993. doi: 10.1111/jth.14247. Epub 2018 Aug 27. J Thromb Haemost. 2018. PMID: 30151972 Free article. Clinical Trial.
101 results